Clinical trial

An Open-Label Proof-of-Principle Study Testing the Use of an Additional MDMA-Assisted Therapy Session in People Who Relapsed After Participating in a Phase 2 Clinical Trial of MDMA-Assisted Therapy to Treat Chronic, Treatment-Resistant Posttraumatic Stress Disorder

Name
MP1-E2
Description
This study will consist of a single session of MDMA-assisted therapy with a full dose of MDMA for people who took part in a study of MDMA-assisted therapy in people with posttraumatic stress disorder (PTSD) whose PTSD symptoms returned to higher levels at least a year after the first MDMA sessions. The single session will be performed by the same pair of therapists who performed the sessions in the first study. People will have a preparatory session, the MDMA-assisted session and three non-drug sessions afterward. Their PTSD symptoms and symptoms of depression will be measured at the start of this study and two and 12 months after the session.
Trial arms
Trial start
2010-12-15
Estimated PCD
2014-06-27
Trial end
2014-06-27
Status
Completed
Phase
Early phase I
Treatment
Midomafetamine
125 mg MDMA followed by 62.5 mg MDMA 1.5 to 2.5 hours later
Arms:
MDMA-assisted therapy
Other names:
MDMA, 3,4-methylenedioxymethamphetamine
Therapy
Non-directive therapy
Arms:
MDMA-assisted therapy
Size
3
Primary endpoint
Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV)
Less than 4 weeks before first experimental session
Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) at 2-month Follow-up
2 months post experimental session
Clinician-Administered PTSD Scale (CAPS-IV)) at 12-month Follow-up
12 months post experimental session
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 2-month Follow-up
Baseline to 2 months post experimental session
Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to 12-month Follow-up
Baseline to 12 months post experimental session
Eligibility criteria
Inclusion Criteria: * Be diagnosed with chronic PTSD; * Have a CAPS score showing moderate to severe PTSD symptoms; * Have participated in MP-1; * Are at least 18 years old; * Must be generally healthy; * Must sign a medical release for the investigators to communicate directly with their therapist and doctors; * Are willing to refrain from taking any psychiatric medications during the study period; * Willing to follow restrictions and guidelines concerning consumption of food, beverages, and nicotine the night before and just prior to each experimental session; * Willing to remain overnight at the study site; * Agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session; * Are willing to be contacted via telephone for all necessary telephone contacts; * Must have a negative pregnancy test if able to bear children, and agree to use an effective form of birth control; * must provide a contact in the event of a participant becoming suicidal; * Are proficient in speaking and reading English; * agree to have all clinic visit sessions recorded to audio and video * Agree not to participate in any other interventional clinical trials during the duration of this study. Exclusion Criteria: * Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control; * Weigh less than 48 kg; * Are abusing illegal drugs; * Are unable to give adequate informed consent; * Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary; * Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 3, 'type': 'ACTUAL'}}
Updated at
2024-01-24

1 organization

1 product

1 indication

Organization
Lykos Therapeutics